S
Satoshi Kunitada
Researcher at Daiichi Sankyo
Publications - 26
Citations - 1675
Satoshi Kunitada is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Factor Xa Inhibitor & Edoxaban. The author has an hindex of 16, co-authored 26 publications receiving 1601 citations.
Papers
More filters
Journal ArticleDOI
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Koichiro Ogata,Jeanne Mendell-Harary,Masaya Tachibana,Hiroshi Masumoto,Toshihiro Oguma,Masazumi Kojima,Satoshi Kunitada +6 more
TL;DR: It is concluded that single and multiple doses of edoxaban are safe and well tolerated up to 150 mg with predictable PK and PD profiles.
Journal ArticleDOI
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Jeffrey I. Weitz,Stuart J. Connolly,Indravadan Patel,Daniel E. Salazar,Shashank Rohatagi,Jeanne Mendell,Helen Kastrissios,Jianqing Jin,Satoshi Kunitada +8 more
TL;DR: The results suggest that in this three-month study, edoxaban 30 or 60 mg qd are safe and well-tolerated.
Journal ArticleDOI
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
Daniel E. Salazar,Jeanne Mendell,Helen Kastrissios,Michelle Green,Timothy J. Carrothers,SaeHeum Song,Indravadan Patel,Tomas S. Bocanegra,Elliott M. Antman,Robert P. Giugliano,Satoshi Kunitada,Bruce E Dornseif,Minggao Shi,Masaya Tachibana,Simon Zhou,Shashank Rohatagi +15 more
TL;DR: Exposure-response analysis found that in patients with NVAF, the incidence of bleeding events increased significantly with increasing edoxaban exposure, with steady-state minimum concentration (Cmin,ss) showing the strongest association.
Journal ArticleDOI
Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.
Mohammad Urooj Zafar,David A. Vorchheimer,Juan Gaztanaga,Mauricio Velez,Daniel Yadegar,Pedro R. Moreno,Satoshi Kunitada,Juan Pagan,Valentin Fuster,Juan J. Badimon +9 more
TL;DR: Direct and specific inhibition of factor Xa by DU-176b significantly reduced ex-vivo thrombus formation at both venous and arterial rheologies, up to 5 hours post-dose, suggesting their potential usefulness for monitoring in a clinical setting.
Journal ArticleDOI
Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers
TL;DR: It was concluded that edoxaban can be administered without regard to food, and both Japanese and Caucasian volunteers demonstrated a modest but clinically insignificant food effect.